Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivos TherapeuticsVVOS -2.28%43 Earnings Yield (Joel Greenblatt) % is -86.96% as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 43/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 96.36% on this metric.
Vivos Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $25.94 Mil.
Vivos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-22.60 Mil. Vivos Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -86.96%.
The historical rank and industry rank for Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
VVOS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -822.91 Med: -85.11 Max: -5.12
Current: -147.06
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Vivos Therapeutics was -5.12%. The lowest was -822.91%. And the median was -85.11%.
VVOS's Earnings Yield (Joel Greenblatt) % is ranked worse than 96.36% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.83
vs VVOS: -147.06
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vivos Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vivos Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Vivos Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vivos Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Vivos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.60 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -86.96% mean?
Vivos Therapeutics (VVOS) has a Earnings Yield (Joel Greenblatt) % of -86.96% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #821 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 96.4%.
Is Vivos Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Vivos Therapeutics' current Earnings Yield (Joel Greenblatt) % is -86.96%. Based on the distribution chart, Vivos Therapeutics ranks #821 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Earnings Yield (Joel Greenblatt) % compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #821 out of 852 companies for Earnings Yield (Joel Greenblatt) %. This places Vivos Therapeutics in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.83, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Earnings Yield (Joel Greenblatt) % is -86.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.38 — trading 66.8% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -86.96%. Vivos Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Earnings Yield (Joel Greenblatt) % is -86.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 66.8% below its estimated GF Value™ of $1.15.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Earnings Yield (Joel Greenblatt) %: -86.96%
GF Value™: $1.15 vs. price of $0.38 (66.8% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
43GF Score
Get the complete analysis for VVOS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
